Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2007 Aug;34(8):1699-707.
Epub 2007 Jul 15.

Health-related quality of life and treatment burden in patients with proliferative lupus nephritis treated with cyclophosphamide or azathioprine/ methylprednisolone in a randomized controlled trial

Affiliations
  • PMID: 17659757
Randomized Controlled Trial

Health-related quality of life and treatment burden in patients with proliferative lupus nephritis treated with cyclophosphamide or azathioprine/ methylprednisolone in a randomized controlled trial

Cecile Grootscholten et al. J Rheumatol. 2007 Aug.

Abstract

Objective: To study prospectively the effect of treatment with cyclophosphamide pulses (CYC) or azathioprine with methylprednisolone (AZA), both for 24-month periods, on health-related quality of life (HRQOL) in patients with proliferative lupus nephritis (LN) in a randomized controlled trial. We expected better HRQOL during AZA treatment.

Methods: HRQOL and disease activity were measured at start and after 12 and 24 months. Generic questionnaires [patient's visual analog scale (VAS), Medical Outcomes Study Short Form-36 Health Survey (SF-36), Profile of Mood States] and a disease-specific measure [Systemic Lupus Erythematosus (SLE) Symptom Checklist] were used. Treatment burden was assessed at 24 months. Disease activity was measured with the SLE Disease Activity Index (SLEDAI) and physician's VAS.

Results: Complete questionnaire data were available from 47 of the 87 patients included in the trial. These patients were representative of the whole group, except that completers were more often Caucasian. HRQOL scores improved significantly during treatment, particularly during the first year, on both generic and disease-specific outcomes. No statistically significant differences were found in HRQOL between the CYC and AZA groups, except for the SF-36 mental component summary scale, which showed more favorable scores in the AZA group. The mean reported treatment burden at 24 months was significantly higher in the CYC group. HRQOL scores did not correlate with the SLEDAI and physician's VAS. The disease activity measures correlated positively with each other.

Conclusion: Treatment of patients with proliferative LN with immunosuppressive drugs and corticosteroids improves HRQOL, particularly in the first year. Due to the small groups studied, the absence of differences between AZA and CYC for most HRQOL scales should be interpreted cautiously: our data suggest that there may be no significant differences. Differences were a higher perceived treatment burden and worse mental HRQOL in the CYC group.

PubMed Disclaimer

Similar articles

Cited by

  • A systematic literature review of the assessment of treatment burden experienced by patients and their caregivers.
    Sheehan OC, Leff B, Ritchie CS, Garrigues SK, Li L, Saliba D, Fathi R, Boyd CM. Sheehan OC, et al. BMC Geriatr. 2019 Oct 11;19(1):262. doi: 10.1186/s12877-019-1222-z. BMC Geriatr. 2019. PMID: 31604424 Free PMC article.
  • The frequency and outcome of lupus nephritis: results from an international inception cohort study.
    Hanly JG, O'Keeffe AG, Su L, Urowitz MB, Romero-Diaz J, Gordon C, Bae SC, Bernatsky S, Clarke AE, Wallace DJ, Merrill JT, Isenberg DA, Rahman A, Ginzler EM, Fortin P, Gladman DD, Sanchez-Guerrero J, Petri M, Bruce IN, Dooley MA, Ramsey-Goldman R, Aranow C, Alarcón GS, Fessler BJ, Steinsson K, Nived O, Sturfelt GK, Manzi S, Khamashta MA, van Vollenhoven RF, Zoma AA, Ramos-Casals M, Ruiz-Irastorza G, Lim SS, Stoll T, Inanc M, Kalunian KC, Kamen DL, Maddison P, Peschken CA, Jacobsen S, Askanase A, Theriault C, Thompson K, Farewell V. Hanly JG, et al. Rheumatology (Oxford). 2016 Feb;55(2):252-62. doi: 10.1093/rheumatology/kev311. Epub 2015 Sep 5. Rheumatology (Oxford). 2016. PMID: 26342222 Free PMC article.
  • A Focus Group Study of Self-Management in Patients With Glomerular Disease.
    Carter SA, Teng C, Gutman T, Logeman C, Cattran D, Lightstone L, Bagga A, Barbour SJ, Barratt J, Boletis J, Caster DJ, Coppo R, Fervenza FC, Floege J, Hladunewich MA, Hogan JJ, Kitching AR, Lafayette RA, Malvar A, Radhakrishnan J, Rovin BH, Scholes-Robertson N, Trimarchi H, Zhang H, Azukaitis K, Cho Y, Viecelli AK, Dunn L, Harris D, Johnson DW, Kerr PG, Laboi P, Ryan J, Shen JI, Ruiz L, Wang AY, Lee AHK, Ka Shun SF, Ka-Hang Tong M, Teixeira-Pinto A, Wilkie M, Alexander SI, Craig JC, Martin A, Tong A. Carter SA, et al. Kidney Int Rep. 2021 Oct 30;7(1):56-67. doi: 10.1016/j.ekir.2021.10.011. eCollection 2022 Jan. Kidney Int Rep. 2021. PMID: 35005314 Free PMC article.
  • Immunosuppressive treatment for proliferative lupus nephritis.
    Tunnicliffe DJ, Palmer SC, Henderson L, Masson P, Craig JC, Tong A, Singh-Grewal D, Flanc RS, Roberts MA, Webster AC, Strippoli GF. Tunnicliffe DJ, et al. Cochrane Database Syst Rev. 2018 Jun 29;6(6):CD002922. doi: 10.1002/14651858.CD002922.pub4. Cochrane Database Syst Rev. 2018. PMID: 29957821 Free PMC article.
  • Lupus nephritis.
    Anders HJ, Saxena R, Zhao MH, Parodis I, Salmon JE, Mohan C. Anders HJ, et al. Nat Rev Dis Primers. 2020 Jan 23;6(1):7. doi: 10.1038/s41572-019-0141-9. Nat Rev Dis Primers. 2020. PMID: 31974366 Review.

Publication types

MeSH terms

LinkOut - more resources